Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | BRAF | P15056 | 14/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173747 | 1.00 | KDM4E (0.63) | KDM4EBRAFDYRK1ADYRK2CYP17A1 | |
| SCHEMBL3172246 | 0.86 | KDM4E (0.65) | KDM4EBRAFCYP17A1RAF1MAPK14 | |
| SCHEMBL3164198 | 0.80 | KDM4E (0.69) | KDM4EBRAFDYRK1ADYRK2CYP17A1 | |
| SCHEMBL3155574 | 0.80 | KDM4E (0.69) | KDM4EBRAFCYP17A1RAF1MAPK14 | |
| SCHEMBL9468075 | 0.80 | KDM4E (0.69) | KDM4EBRAFDYRK1ADYRK2CYP17A1 | |
| SCHEMBL3175469 | 0.79 | KDM4E (0.83) | KDM4EBRAFDYRK1B | |
| SCHEMBL11464152 | 0.78 | KDM4E (0.81) | KDM4EBRAFDYRK1B | |
| SCHEMBL11461883 | 0.78 | KDM4E (0.67) | KDM4EBRAFCYP17A1RAF1MAPK14 | |
| SCHEMBL8435070 | 0.77 | KDM4E (1.00) | KDM4EBRAFDYRK1B | |
| SCHEMBL4700538 | 0.77 | KDM4E (0.63) | KDM4EBRAFCYP17A1RAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | KDM4E 3705/4885BRAF 148/4885DYRK1A 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.